Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
10.47
-1.41 (-11.87%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Nurix Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is December - November.
Millions USD. Fiscal year is Dec - Nov.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 | Nov '20 Nov 30, 2020 | 2019 - 2018 |
| Cash & Equivalents | 110 | 54.63 | 64.47 | 80.51 | 119.36 | Upgrade
|
| Short-Term Investments | 499.59 | 233.28 | 244.67 | 215.21 | 161.79 | Upgrade
|
| Cash & Short-Term Investments | 609.58 | 287.91 | 309.14 | 295.72 | 281.15 | Upgrade
|
| Cash Growth | 111.73% | -6.87% | 4.54% | 5.18% | 645.36% | Upgrade
|
| Accounts Receivable | - | - | - | 6 | 7.5 | Upgrade
|
| Other Receivables | 1.5 | 0.8 | 1.1 | 1.1 | 4.25 | Upgrade
|
| Receivables | 1.5 | 0.8 | 1.1 | 7.1 | 11.75 | Upgrade
|
| Prepaid Expenses | 8.3 | 6.8 | 8.21 | 8.29 | 5.54 | Upgrade
|
| Total Current Assets | 619.39 | 295.5 | 318.45 | 311.12 | 298.43 | Upgrade
|
| Property, Plant & Equipment | 45.9 | 47.95 | 29.51 | 25.35 | 6.67 | Upgrade
|
| Long-Term Investments | - | 7.42 | 63.88 | 137.19 | 90.89 | Upgrade
|
| Long-Term Deferred Charges | 0.1 | 0.5 | 0.5 | 0.5 | - | Upgrade
|
| Other Long-Term Assets | 3.96 | 4.22 | 4.42 | 2.62 | 0.35 | Upgrade
|
| Total Assets | 669.34 | 355.6 | 416.76 | 476.77 | 396.34 | Upgrade
|
| Accounts Payable | 11.48 | 6.4 | 5.06 | 6.65 | 3.41 | Upgrade
|
| Accrued Expenses | 34.48 | 24.19 | 20.84 | 13.82 | 7.55 | Upgrade
|
| Current Portion of Leases | 8.01 | 7.49 | 5.53 | 3.85 | - | Upgrade
|
| Current Income Taxes Payable | 1.24 | 0.03 | 0.09 | 0.08 | 0.07 | Upgrade
|
| Current Unearned Revenue | 38.36 | 48.1 | 37.63 | 41.21 | 32.8 | Upgrade
|
| Other Current Liabilities | 2.28 | 0.75 | 1.5 | 0.66 | 0.7 | Upgrade
|
| Total Current Liabilities | 95.85 | 86.96 | 70.66 | 66.26 | 44.54 | Upgrade
|
| Long-Term Leases | 20.29 | 23.13 | 6.43 | 9.19 | - | Upgrade
|
| Long-Term Unearned Revenue | 26.21 | 45.02 | 35.97 | 59.02 | 60.69 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 0.85 | Upgrade
|
| Total Liabilities | 142.35 | 155.11 | 113.06 | 134.47 | 106.07 | Upgrade
|
| Common Stock | 0.08 | 0.05 | 0.05 | 0.05 | 0.04 | Upgrade
|
| Additional Paid-In Capital | 1,266 | 746.3 | 709.22 | 563.76 | 393.84 | Upgrade
|
| Retained Earnings | -738.77 | -545.2 | -401.25 | -220.89 | -103.7 | Upgrade
|
| Comprehensive Income & Other | 0.15 | -0.66 | -4.32 | -0.61 | 0.09 | Upgrade
|
| Total Common Equity | 526.99 | 200.49 | 303.7 | 342.3 | 290.27 | Upgrade
|
| Shareholders' Equity | 526.99 | 200.49 | 303.7 | 342.3 | 290.27 | Upgrade
|
| Total Liabilities & Equity | 669.34 | 355.6 | 416.76 | 476.77 | 396.34 | Upgrade
|
| Total Debt | 28.3 | 30.61 | 11.96 | 13.04 | - | Upgrade
|
| Net Cash (Debt) | 581.28 | 264.72 | 361.06 | 419.87 | 281.15 | Upgrade
|
| Net Cash Growth | 119.59% | -26.68% | -14.01% | 49.34% | 645.36% | Upgrade
|
| Net Cash Per Share | 8.66 | 4.87 | 7.43 | 9.79 | 17.94 | Upgrade
|
| Filing Date Shares Outstanding | 75.89 | 48.89 | 47.27 | 44.74 | 38.91 | Upgrade
|
| Total Common Shares Outstanding | 75.87 | 48.72 | 47.17 | 44.66 | 38.86 | Upgrade
|
| Working Capital | 523.53 | 208.55 | 247.79 | 244.86 | 253.9 | Upgrade
|
| Book Value Per Share | 6.95 | 4.12 | 6.44 | 7.66 | 7.47 | Upgrade
|
| Tangible Book Value | 526.99 | 200.49 | 303.7 | 342.3 | 290.27 | Upgrade
|
| Tangible Book Value Per Share | 6.95 | 4.12 | 6.44 | 7.66 | 7.47 | Upgrade
|
| Machinery | 41.04 | 33.83 | 27.62 | 19.3 | 15.37 | Upgrade
|
| Leasehold Improvements | 5.14 | 3.24 | 3.83 | 3.08 | 2.66 | Upgrade
|
Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.